Detailed Information on Publication Record
2021
Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly
SOUKUP, Jiri, Helena HORNYCHOVA, Monika MANETHOVA, Kvetoslava MICHALOVA, Ludmila MICHNOVA et. al.Basic information
Original name
Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly
Authors
SOUKUP, Jiri (203 Czech Republic), Helena HORNYCHOVA (203 Czech Republic), Monika MANETHOVA (203 Czech Republic), Kvetoslava MICHALOVA (203 Czech Republic), Ludmila MICHNOVA (203 Czech Republic), Lenka POPOVSKA (203 Czech Republic), Veronika SKARKOVA (203 Czech Republic), Tomas CESAK (203 Czech Republic), David NETUKA (203 Czech Republic), Ales RYSKA (203 Czech Republic), Jan CAP (203 Czech Republic), Vaclav HANA (203 Czech Republic), Vaclav, Jr. HANA (203 Czech Republic), Michal KRSEK (203 Czech Republic), Eva DVORAKOVA (203 Czech Republic), Michal KRCMA (203 Czech Republic), Ivica LAZUROVA (703 Slovakia), Věra OLŠOVSKÁ (203 Czech Republic, belonging to the institution), Karel STARÝ (203 Czech Republic, belonging to the institution), Peter VANUGA (703 Slovakia) and Filip GABALEC (203 Czech Republic)
Edition
Journal of Cellular and Molecular Medicine, HOBOKEN, Wiley Blackwell, 2021, 1582-1838
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
10601 Cell biology
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 5.295
RIV identification code
RIV/00216224:14110/21:00121110
Organization unit
Faculty of Medicine
UT WoS
000610837800001
Keywords in English
acromegaly; PITNET; pituitary neoplasm; somatostatin receptor
Tags
International impact, Reviewed
Změněno: 7/6/2021 14:23, Mgr. Tereza Miškechová
Abstract
V originále
In somatotroph pituitary tumours, somatostatin analogue (SSA) therapy outcomes vary throughout the studies. We performed an analysis of cohort of patients with acromegaly from the Czech registry to identify new prognostic and predictive factors. Clinical data of patients were collected, and complex immunohistochemical assessment of tumour samples was performed (SSTR1-5, dopamine D2 receptor, E-cadherin, AIP). The study included 110 patients. In 31, SSA treatment outcome was evaluated. Sparsely granulated tumours (SGST) differed from the other subtypes in expression of SSTR2A, SSTR3, SSTR5 and E-cadherin and occurred more often in young. No other clinical differences were observed. Trouillas grading system showed association with age, tumour size and SSTR2A expression. Factors significantly associated with SSA treatment outcome included age, IGF1 levels, tumour size and expression of E-cadherin and SSTR2A. In the group of SGST, poor SSA response was observed in younger patients with larger tumours, lower levels of SSTR2A and higher Ki67. We observed no relationship with expression of other proteins including AIP. No predictive value of E-cadherin was observed when tumour subtype was considered. Multiple additional factors apart from SSTR2A expression can predict treatment outcome in patients with acromegaly.